Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program. As of June 13, 2025, the company has repurchased a total of 4,027,331 ordinary fully paid securities, including 27,825 securities bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is listed on the Australian Securities Exchange under the code NEU.
Average Trading Volume: 716,166
Technical Sentiment Signal: Buy
Current Market Cap: A$1.77B
Learn more about NEU stock on TipRanks’ Stock Analysis page.